Gonorrhea continues to be a major US public health problem in terms of its prevalence as week as the lack of effective treatments available.
Gonorrhea, caused by the bacterium, Neisseria gonorrhoeae, continues to be a major US public health problem in terms of its prevalence as well as the lack of effective treatments available.
Multidrug-resistant gonorrhea is a growing problem that the Centers for Disease Control and Prevention (CDC) has based on the evidence that cephalosporin resistance may be emerging in the United States, according to the February 15, 2013, Morbidity and Mortality Weekly Report (MMWR).
“Gonorrhea is the second most commonly reported notifiable infection in the United States; >300,000 cases were reported in 2011,” according the CDC Grand Rounds. “In the United States, health inequities persist; the incidence of reported gonorrhea among blacks is 17 times the rate among whites, likely because of structural socioeconomic factors.”
Ongoing surveillance of gonococcal antimicrobial resistance has been undertaken by the CDC since 1986, with the introduction of the Gonococcal Isolate Surveillance Project (GISP). This system monitors gonococcal antimicrobial susceptibility from urethal N gonorrhoeae isolates that have been collected from men at STD clinics. These results help to form gonorrhea treatment recommendations before a major public health problem develops, according to the MMWR article.
“Cefiximine minimum inhibitory concentrations (MICs) recently increased, suggesting that the effectiveness of cefixime might be threatened,” the authors said. “The percentage of isolates with elevated cefixime MICs (≥0.25 µg/mL) increased from 0.1% in 2006 to 1.4% in 2011.”
The populations with higher increases in isolates were seen from men in the western United States and from men who have sex with men, which is the place where the fluoroquinolone-resistant N gonorrhoeae was first seen.
In 2011, approximately 12% of the isolates could no longer be treated with penicillin, about 23% could not be treated with tetracycline, and 13% were resistant to fluoroquinolones. With the development of cephalosporin resistance to the bacterium, treatment of gonorrhea has become much more complicated.
CDC currently recommends treatment of gonorrhea at any anatomic site with a single dose of 250 mg intramuscular ceftriaxone, which should then be followed with either one single dose of 1 g of azithromycin or 100 mg of doxycycline orally twice daily for 7 days. CDC also offers 2 alternative treatments for urogenital and rectal gonorrhea:
1) cefixime 400 mg as single oral dose and either azithromycin 1 g as a single oral dose or the doxycycline regimen above.
2) If the patient is allergic to cephalosporins, a single oral dose of azithromycin 2 g can be taken. Patients must return in a week to be tested for a cure, the authors noted.
At the moment, only 1 new antimicrobial is being tested in a clinical study for the treatment of gonorrhea. The National Institutes of Health has provided funding for more than 130 research grants on gonorrhea, including research to identify other targets for antimicrobial development. Unfortunately, a vaccine has not yet been developed, but research on this is in the works. â
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.